Physician profile
David Calderwood
NPI 1235110586
$2,421.64
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $832 · 2020: $841 · 2021: $602 · 2023: $20.11 · 2024: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $146.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $562.39 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $221.59 | 2019-2020 | |
| Allergan, INC. | $177.86 | 2019-2021 | |
| Amgen INC. | $141.00 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.65 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.27 | 2019-2021 | |
| Mirum Pharmaceuticals, INC. | $125.89 | 2024 | Livmarli |
| Abbvie INC. | $99.76 | 2020-2021 | |
| Lilly USA, LLC | $95.93 | 2019-2021 | |
| Amarin Pharma, INC. | $95.79 | 2020-2021 | |
| Esperion Therapeutics, INC. | $84.50 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $76.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $72.86 | 2019-2020 | |
| Eisai INC. | $63.15 | 2020-2021 | |
| Pfizer INC. | $58.74 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $50.08 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $31.76 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $29.47 | 2019 | |
| Currax Pharmaceuticals LLC | $28.71 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.66 | 2019 | |
| Glaxosmithkline, LLC. | $20.11 | 2023 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $19.49 | 2020 | |
| Shire North American Group INC | $18.62 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.09 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.41 | 2019 | |
| Adlon Therapeutics L.P. | $11.99 | 2020 | |
| Zyla Life Sciences, INC. | $11.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Calderwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.